One recent study has demonstrated that dual inhibition of AKT/PI3K and MAPK signalling increases the sensitivity of pancreatic ductal adenocarcinoma to paclitaxel/gemcitabine chemotherapy.38 Here, AKT1 is linked to pancreatic ductal adenocarcinoma.